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Abstract
We present a case of haemolytic uraemic syndrome (HUS) in a 16-year-old female with serological evidence of acute
Escherichia coli O157:H7 infection. She progressed to established renal failure and received a deceased donor kidney transplant.
Shiga toxin–associated HUS (STEC-HUS) does not recur following renal transplantation, but unexpectedly this patient did ex-
perience rapid and severe HUS recurrence. She responded to treatment with the terminal complement inhibitor eculizumab
and subsequent genetic analysis revealed a rare variant in a complement gene. This highlights the importance of genetic ana-
lysis in patients with STEC-HUS prior to renal transplantation so that management can be individualized.
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Introduction
Haemolytic uraemic syndrome (HUS) is characterized by the
clinical triad of acute kidney injury (AKI), thrombocytopenia
and microangiopathic haemolytic anaemia (MAHA) [1]. The
most common form is caused by enteric infection with Shiga
toxin–producing bacteria, most frequently Escherichia coli sero-
type O157:H7 [2], known as STEC-HUS, with an estimated inci-
dence in the UK of 7.1 per million [3]. STEC-HUS is a rare (5%)
self-limiting illness with consequent established renal failure
(ERF) [4].
The atypical form of HUS (aHUS) is usually associated with
dysregulation of the complement system resulting from in-
herited or acquired defects. It is rare (UK incidence 0.42 per mil-
lion [5]), but historically has been associated with a poor
outcome (>50% ERF) [6, 7]. Additionally, due to the genetic na-
ture of the disease, aHUS recurrence following renal transplant-
ation and subsequent graft loss was the rule in those with
mutations in liver-produced serum complement proteins [1, 8–
10]. The development of the terminal complement inhibitor
eculizumab has transformed the management and prognosis of
aHUS and the outcome following renal transplantation [5, 11].
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Exceptional Case
In contrast, recurrence of HUS after renal transplantation does
not occur in STEC-HUS [8, 9].
We report a case of HUS in a 16-year-old female with sero-
logical evidence of acute E. coli O157:H7 infection that resulted
in ERF; she experienced rapid and severe recurrence of HUS fol-
lowing renal transplantation, and subsequent analysis identi-
fied a rare genetic variant in C3.
Case report
A 16-year-old female presented with AKI (creatinine 324 mmol/L)
and a 4-day history of vomiting without diarrhoea. Her only
past medical history was acne, and Roaccutane had been com-
menced 1 month earlier; blood tests performed at that time
were all normal. Her mother had been unwell with a diarrhoeal
illness 2 weeks previously.
Blood tests on admission were consistent with a thrombotic
microangiopathy (TMA): haemoglobin 9.9 g/dL, platelets 41  109/
L, bilirubin 38 mmol/L, lactate dehydrogenase (LDH) 1865 U/L, re-
ticulocytes 107  109/L and red blood cell fragmentation on the
blood film; Coombs test was negative and coagulation was nor-
mal. Treatment with plasma exchange was commenced (total of
eight exchanges) and thrombotic thrombocytopenic purpura (TTP)
was excluded (ADAMTS13 activity 76%). The National Health
Protection Agency (HPA) laboratory reported that immunoglobulin
M (IgM) antibodies to E. coli O157 lipopolysaccharide (LPS) were
positive, in keeping with acute STEC-HUS [10]. Levels of C3, C4,
factor H and factor I were normal. Her renal function deteriorated
and she required haemodialysis, as well as ventilatory and ino-
tropic support in the intensive care unit (ICU) consequent to a hos-
pital-acquired pneumonia. There was no recovery in renal
function and she remained on haemodialysis. A kidney biopsy
was performed 3 months later, showing features of TMA; im-
munofluorescence showed segmental C3 deposition in the glom-
erular tuft. Later, 10 months after presentation, she was admitted
with seizures that were attributed to hypertensive encephalop-
athy (computed tomography of the brain and cerebrospinal fluid
examination were normal) and she was again managed in the ICU
for ventilatory support and blood pressure control.
She received a donor after brain death (DBD) renal transplant
with a 1:1:0 human leucocyte antigen mismatch 18 months after
her initial presentation. She received basiliximab and methyl-
prednisolone at induction with maintenance tacrolimus, myco-
phenolate mofetil (MMF) and prednisolone. A transplant biopsy
performed 7 days post-operatively due to delayed graft function
showed borderline acute T-cell–mediated rejection and no evi-
dence of TMA; she was treated with intravenous methylpredni-
solone, but her renal function deteriorated concurrent with a
decrease in her platelet count and an increase in LDH, with a
peak creatinine of 396 mmol/L. At Day 10 she developed MAHA
and was treated with plasma exchange. Tacrolimus levels were
therapeutic. The following day she had multiple generalized ton-
ic–clonic seizures, severe headache, photophobia and blurred vi-
sion, which progressed to cortical blindness over the course of 4 h
in the context of a blood pressure of 190/113 mmHg. Magnetic
resonance imaging (MRI) of the brain was consistent with poster-
ior reversible encephalopathy syndrome (PRES) (Figure 1A). She
was admitted to the ICU for management of hypertension and
treatment with eculizumab was commenced. The neurological
symptoms resolved within 48 h and over the following 2 weeks
the renal function improved and haematological parameters
normalized. A transplant biopsy performed 15 days post-opera-
tively demonstrated severe acute TMA and borderline acute T-
cell–mediated rejection (Figure 1Bi–ii).
Subsequent genetic analysis identified a heterozygous rare
genetic variant in C3: c.4855A>C p.(Ser1619Arg). The functional
significance has not been assessed, however, the amino acid is
well conserved, in silico analysis suggests that the variant is pos-
sibly deleterious and structural modelling (Figure 1C) demon-
strates that this is in the same C3 domain as the variant c.4973T
>C p.(Val1658Ala) demonstrated by Sartz et al. to be functionally
significant [12].
A transplant biopsy performed 3 months post-operatively for
proteinuria (urine protein:creatinine ratio 243 mg/mmol) showed
no significant abnormality. A fourth transplant biopsy was per-
formed 5 months post-operatively because the creatinine rose
from 130 to 180 mmol/L. This showed acute T-cell–mediated rejec-
tion (Banff IB) (Figure 1Biii) and she was treated with intravenous
methylprednisolone. Immunofluorescence, including kappa and
lambda, was negative. She remains on eculizumab, prednisolone,
tacrolimus and MMF, and 3 years after transplantation she is well
and creatinine is 157 mmol/L.
Discussion
This patient presented with a TMA and normal ADAMTS13 activ-
ity, and although she had no history of diarrhoea, she had sero-
logical evidence (positive IgM) of recent E. coli O157:H7 infection
consistent with a diagnosis of STEC-HUS. However, a faecal spe-
cimen was not analysed and the serodiagnosis is sensitive but
not specific for verocytotoxin-producing E. coli (VTEC) [15]. In add-
ition, serum antibodies to the LPS of E. coli 0157 have been de-
tected in healthy people in rural communities in the UK [10]. The
absence of diarrhoea does not preclude STEC-HUS [2] and 5% of
people with STEC-HUS may not have diarrhoea [16]. We recom-
mend that all patients with HUS, even those without a history of
diarrhoea, be investigated for STEC infection by culture and Shiga
toxin polymerase chain reaction on a faecal specimen, as well as
serological testing, to optimize sensitivity [17, 18].
STEC-HUS is said not to recur following renal transplantation
[8, 9]; however, a severe TMA evolved within 1 week of trans-
plantation, resulting in AKI and neurological manifestations. She
responded promptly to treatment with the terminal complement
inhibitor eculizumab. Subsequent genetic analysis revealed the
p.(Ser1619Arg) heterozygous rare genetic variant in C3 [12].
Historically, aHUS recurrence following transplantation has
occurred in 60% of patients, with the highest risk observed in pa-
tients with mutations in CFH and C3 [1, 19, 20]. This patient had
seizures 10 months after the initial presentation and neurological
symptoms during the recurrence after transplantation; it is not
known whether extrarenal manifestations occur consequent to
AKI, hypertension, TMA or complement dysregulation [21].
Very rare cases of STEC-HUS infection unmasking latent com-
plement defects and triggering aHUS have been described [22–25]
and Alberti et al. [26] also reported post-transplant recurrence
leading to graft loss in two patients with STEC-HUS who were
subsequently found to have complement gene mutations.
In this case, due to ongoing proteinuria, for disease reso-
lution we looked for evidence of eculizumab deposition in the
renal biopsy as described by Herlitz et al. in C3G [27]. That we
were unable to detect immunoglobulin G (IgG) kappa deposition
may reflect the differing nature of complement activation in
aHUS compared with C3G.
In summary, as ERF following STEC-HUS is rare and a priori
knowledge of an underlying complement mutation allows
prophylactic eculizumab to be given, genetic screening should
be performed in all individuals who develop ERF following
STEC-HUS and who are being considered for transplantation, as
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recommended in a 2015 Kidney Disease: Improving Global
Outcomes consensus document [21]. This personalized ap-
proach to HUS will prevent the morbidity and mortality associ-
ated with recurrent disease [28].
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